Compare Heron Therapeutics Inc (HRTX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sibanye Stillwater Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Sibanye Stillwater Ltd trades at $9.99 (market cap $6.88B). The key difference: Sibanye Stillwater Ltd is far larger — about 101.2× Heron Therapeutics Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Sibanye Stillwater Ltd for 51 Days on average.
| HRTX | SBSW | |
|---|---|---|
Market Cap | $68.01M | $6.88B |
Volume | 1,891,941 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $21.12 |
52-Week Low | $0.27 | $8.00 |
Typical Hold Time | 35 Days | 51 Days |
Enterprise Value | $174.75M | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
SBSW trades at $9.99, up 3.2% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong operational improvement with 2025 revenue reaching $129.68B and positive net cash flow of $1.13B, though it posted a net loss of $5.17B. Recent Q2 2026 earnings beat expectations with $1.34 EPS versus $1.26 expected, indicating potential turnaround momentum. Analyst consensus remains positive with a $14.25 price target representing 43% upside potential from current levels.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 8.12, P/S 0.7) and strong profitability metrics (ROE 34.37%), but faces execution risks from recent net losses and high debt levels. Key catalysts include continued operational improvements and commodity price support, while risks involve debt management and margin pressures. Institutional sentiment appears constructive with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
